Replies to post #87796 on Biotech Values

[jb_118]

Although today’s SEC filing says that some of the $15M attributable to M178 could still be received, I don’t think investors should count on it. Thus, the realistic milestone figure from the 2006 NVS collaboration is now $163M, which consists of milestones pertaining to Lovenox and Copaxone.

MNTA received $5M for lovenox approval, leaving $158M on the table. Any ideas as to how the rest of this breaks down? I don't recall any discussion on it from MNTA recently.